FREE RAC Regulatory Submissions and Approval Questions and Answers

Question 1

A pharmaceutical company is preparing a marketing application for a new chemical entity to be submitted in the US, EU, and Japan. Which document provides a harmonized structure for the quality, nonclinical, and clinical sections of the application, thereby streamlining the submission process across these regions?

Accepted Answer

Common Technical Document (CTD)

Answer

The Common Technical Document (CTD), developed by the International Council for Harmonisation (ICH), provides a standardized format for regulatory submissions in the ICH regions (US, EU, Japan). It is organized into five modules, with Modules 2 through 5 being common across regions, which significantly reduces the effort needed to compile applications for different regulatory authorities.

Question 2

A medical device company is preparing a premarket submission for a new Class II diagnostic device. The device has the same intended use and similar technological characteristics as a legally marketed device (a predicate device). Which type of submission is MOST appropriate to seek marketing authorization in the United States?

Accepted Answer

Premarket Notification (510(k))

Answer

A Premarket Notification (510(k)) is the appropriate submission pathway for a device that is substantially equivalent to a legally marketed predicate device. This pathway is used for most Class II devices and some Class I devices. The submission's purpose is to demonstrate that the new device is as safe and effective as the predicate.

Question 3

A sponsor of an approved Class III medical device is required to submit post-approval reports to the FDA to ensure continued safety and effectiveness. Which of the following is a mandatory reporting requirement for the holder of an approved Premarket Approval (PMA) application?

Accepted Answer

Periodic Medical Device Reports (MDRs) for adverse events and annual reports.

Answer

Holders of an approved PMA are subject to post-approval requirements, which include submitting Medical Device Reports (MDRs) for deaths, serious injuries, and certain malfunctions as per 21 CFR 803. They are also typically required to submit annual reports summarizing new safety and effectiveness information.

Question 4

A pharmaceutical sponsor has an active Investigational New Drug (IND) application for a product in Phase 2 clinical trials. According to FDA regulations (21 CFR 312.33), what must the sponsor submit to the FDA within 60 days of the anniversary date of the IND going into effect?

Accepted Answer

An IND Annual Report

Answer

Under 21 CFR 312.33, sponsors are required to submit an IND Annual Report to the FDA. This report must be submitted within 60 days of the anniversary of the date the IND went into effect and should summarize the status of ongoing studies, provide a summary of the previous year's findings, and update any new information.

Question 5

When preparing the technical documentation for a medical device to be marketed in the European Union under the Medical Device Regulation (MDR - EU 2017/745), which of the following is a critical component required in Annex II?

Accepted Answer

A detailed description of the design and manufacturing processes.

Answer

Annex II of the EU MDR outlines the required contents of the technical documentation. A key element is detailed information concerning the design and manufacture of the device. This includes drawings, specifications, and a description of the manufacturing methods and facilities to demonstrate conformity with the General Safety and Performance Requirements.

(RAC) Regulatory Affairs Certification Practice Test

(RAC) Regulatory Affairs Certification Practice Test

FREE RAC Regulatory Submissions and Approval Questions and Answers